FARN — Faron Pharmaceuticals Oy Income Statement
0.000.00%
Last trade - 00:00
- £231.22m
- £216.65m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.1 | 16.7 | 21.1 | 27.4 | 28.6 |
Operating Profit | -13.1 | -16.7 | -21.1 | -27.4 | -28.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.3 | -16.9 | -21.2 | -28.7 | -30.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.3 | -16.9 | -21.2 | -28.7 | -30.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.3 | -16.9 | -21.2 | -28.7 | -30.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.3 | -16.9 | -21.2 | -28.7 | -30.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.262 | -0.26 | -0.293 | -0.365 | -0.334 |
Dividends per Share |